API | levomilnacipran

levomilnacipran (fetzima) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Levomilnacipran (1S, 2R/F2695) is an enantiomer of milnacipran, a serotonin/norepinephrine (5-HT/NE) reuptake inhibitor. Levomilnacipran is pharmacologically more active as compared with racemic mixture and dextromilnacipran (1R, 2S/F2696). The safety of the drug is also higher than the safety of a racemate, resulting in a beneficial impact on the therapeutic effect. Pierre Fabre and Forest Laboratories are developing levomilnacipran extended release (ER) [FETZIMA™], an enantiomer of milnacipran, for the treatment of major depressive disorder (MDD). In addition, Pierre Fabre (the originator of the compound) is developing the drug to improve recovery in patients with ischaemic stroke. ^NCATS

Chemistry

SMILES: CCN(CC)C(=O)[C@]1(C[C@H]1CN)c2ccccc2
InChIKey: GJJFMKBJSRMPLA-DZGCQCFKSA-N
Mol. Mass: 246.35
ALogP: 1.77 Partition coefficient
ChEMBL Molecules:

levomilnacipran

levomilnacipran hydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- Sodium-dependent noradrenaline transporter (Homo sapiens) ^UniProt
- Sodium-dependent serotonin transporter (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

Drug Pricing (per unit)

United States

$9.6717 - $13.8395

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (14)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (9)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (1)

Depressive Disorder, Major

Experimental Indications - Clinical Trial Phases 1-4 (3)

Depressive Disorder, Major (Phase 4)

Healthy Volunteers (Phase 4)

Stroke (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue